Pediatric Mitral Valve Insufficiency Medication
- Author: Monesha Gupta, MD, MBBS, FAAP, FACC, FASE; Chief Editor: Stuart Berger, MD more...
Medication Summary
ACE inhibitors and diuretics are the mainstay of medical therapy for patients with mitral regurgitation (MR).
Afterload reducers
Class Summary
These agents are used to improve preoperative or postoperative cardiac output. They reduce systemic vascular resistance and increase systemic blood flow resulting from myocardial dysfunction, significant mitral valve insufficiency, or both.
Captopril (Capoten)
Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, resulting in lower aldosterone secretion.
By decreasing the systemic blood pressure, ACE inhibitors decrease the amount of work placed on the heart. The regurgitant fraction also is decreased because of the lower systemic blood pressure.
Hydralazine (Apresoline)
Decreases systemic resistance through direct vasodilation of arterioles.
Nifedipine (Procardia, Adalat)
Relaxes coronary smooth muscle and produces coronary vasodilation, which in turn improves myocardial oxygen delivery.
Nitroprusside (Nitropress)
Afterload-reducing agent used for acute MR. Produces vasodilation and increases inotropic activity of the heart. At higher doses, may exacerbate myocardial ischemia by increasing the heart rate.
Diuretic agents
Class Summary
These agents promote excretion of water and electrolytes by the kidneys. They are used to treat heart failure or hepatic, renal, or pulmonary disease when sodium and water retention have resulted in edema or ascites.
Furosemide (Lasix)
Increases excretion of water by interfering with chloride-binding cotransport system, which in turn, inhibits sodium and chloride reabsorption in ascending loop of Henle and distal renal tubule. Dose must be individualized. Depending on response, administer at increments of 20-40 mg, no sooner than 6-8 h after the previous dose, until desired diuresis occurs. When treating infants, titrate using increments of 1 mg/kg/dose until a satisfactory effect is achieved.
Spironolactone (Aldactone)
For management of edema resulting from excessive aldosterone excretion. Competes with aldosterone for receptor sites in distal renal tubules, increasing water excretion while retaining potassium and hydrogen ions.
Ethacrynic acid (Edecrin)
Use as a second-line IV diuretic for those with congestive heart failure. Inhibits loop of Henle and proximal and distal convoluted tubule sodium and chloride resorption.
Inotropic agents
Class Summary
These are effective medications when cardiac function is slightly decreased or compromised by the amount of mitral regurgitation. Positive inotropic agents increase the force of contraction of the myocardium and are used to treat acute and chronic congestive heart failure. Some agents may also increase or decrease the heart rate (ie, positive or negative chronotropic agents), provide vasodilatation, or improve myocardial relaxation. These additional properties influence the choice of drug for specific circumstances. Cardiac glycosides are used predominantly for their inotropic effects.
Digoxin (Lanoxin)
Cardiac glycoside with direct inotropic effects in addition to indirect effects on the cardiovascular system. Acts directly on cardiac muscle, increasing myocardial systolic contractions. Its indirect actions result in increased carotid sinus nerve activity and enhanced sympathetic withdrawal for any given increase in mean arterial pressure.
Milrinone (Primacor)
Bipyridine-positive inotropic agent and vasodilator with little chronotropic activity. Different in mode of action from both digitalis glycosides and catecholamines.
Anticoagulants
Class Summary
These agents prevent recurrent or ongoing thromboembolic occlusion of the vertebrobasilar circulation. Lifelong anticoagulation therapy is needed in patients with mechanical valves.
Warfarin (Coumadin)
Interferes with hepatic synthesis of vitamin K–dependent coagulation factors. Used for prophylaxis and treatment of venous thrombosis, pulmonary embolism, and thromboembolic disorders. Tailor dose to maintain an INR in the range of 2-3.
Ahmed MI, McGiffin DC, O'Rourke RA, Dell'Italia LJ. Mitral regurgitation. Curr Probl Cardiol. Mar 2009;34(3):93-136. [Medline].
Rahimtoola SH. The mitral valve is a complex structure. Foreword. Curr Probl Cardiol. Mar 2009;34(3):89. [Medline].
Park SM, Park SW, Casaclang-Verzosa G, et al. Diastolic dysfunction and left atrial enlargement as contributing factors to functional mitral regurgitation in dilated cardiomyopathy: data from the Acorn trial. Am Heart J. Apr 2009;157(4):762.e3-10. [Medline].
Pederzolli N, Agostini F, Fiorani V, et al. Postendocarditis mitral valve aneurysm. J Cardiovasc Med (Hagerstown). Mar 2009;10(3):259-60. [Medline].
Carpentier A. Congenital malformations of the mitral valve. In: Stark J, de Laval M, eds. Surgery for Congenital Heart Defects. WB Saunders Co; 1983:467-82.
Little SH, Pirat B, Kumar R, et al. Three-dimensional color Doppler echocardiography for direct measurement of vena contracta area in mitral regurgitation: in vitro validation and clinical experience. JACC Cardiovasc Imaging. Nov 2008;1(6):695-704. [Medline].
Calafiore AM, Gallina S, Iaco AL, et al. Mitral valve surgery for functional mitral regurgitation: should moderate-or-more tricuspid regurgitation be treated? a propensity score analysis. Ann Thorac Surg. Mar 2009;87(3):698-703. [Medline].
Wan CK, Suri RM, Li Z, et al. Management of moderate functional mitral regurgitation at the time of aortic valve replacement: is concomitant mitral valve repair necessary?. J Thorac Cardiovasc Surg. Mar 2009;137(3):635-640.e1. [Medline].
Bernal JM, Gutierrez F, Farinas MC, et al. Use of mitral homograft to support a mechanical valve prosthesis: a feasible solution for recurrent mitral valve dysfunction. J Thorac Cardiovasc Surg. Mar 2009;137(3):762-3. [Medline].
Anderson RH, Wilcox BR. The anatomy of the mitral valve. In: Wells FC, Shapiro LM, eds. Mitral Valve Disease. 2nd ed. Butterworth-Heinemann; 1996:4-13.
Barlow JB. Mitral regurgitation. In: Perspectives on the Mitral Valve. FA Davis Co; 1987:113-31.
Carabello BA. Mitral valve regurgitation. Curr Probl Cardiol. Apr 1998;23(4):202-41. [Medline].
Dunn JM. Porcine valve durability in children. Ann Thorac Surg. Oct 1981;32(4):357-68. [Medline].
Eckberg DL, Gault JH, Bouchard RL, et al. Mechanics of left ventricular contraction in chronic severe mitral regurgitation. Circulation. Jun 1973;47(6):1252-9. [Medline].
Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med. Mar 3 2005;352(9):875-83. [Medline].
Kolibash AJ Jr, Kilman JW, Bush CA, et al. Evidence for progression from mild to severe mitral regurgitation in mitral valve prolapse. Am J Cardiol. Oct 1 1986;58(9):762-7. [Medline].
Kon MW, Myerson SG, Moat NE, Pennell DJ. Quantification of regurgitant fraction in mitral regurgitation by cardiovascular magnetic resonance: comparison of techniques. J Heart Valve Dis. Jul 2004;13(4):600-7. [Medline].
Krivokapich J. Echocardiography in valvular heart disease. Curr Opin Cardiol. Mar 1994;9(2):158-63. [Medline].
Magovern JH, Moore GW, Hutchins GM. Development of the atrioventricular valve region in the human embryo. Anat Rec. Jun 1986;215(2):167-81. [Medline].
Perloff JK, Roberts WC. The mitral apparatus. Functional anatomy of mitral regurgitation. Circulation. Aug 1972;46(2):227-39. [Medline].
Shimoyama H, Sabbah HN, Rosman H, et al. Effects of long-term therapy with enalapril on severity of functional mitral regurgitation in dogs with moderate heart failure. J Am Coll Cardiol. Mar 1 1995;25(3):768-72. [Medline].
Skoularigis J, Sinovich V, Joubert G, Sareli P. Evaluation of the long-term results of mitral valve repair in 254 young patients with rheumatic mitral regurgitation. Circulation. Nov 1994;90(5 Pt 2):II167-74. [Medline].
Tribouilloy C, Shen WF, Leborgne L, et al. Comparative value of Doppler echocardiography and cardiac catheterization for management decision-making in patients with left-sided valvular regurgitation. Eur Heart J. Feb 1996;17(2):272-80. [Medline].
Print
